![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Copyright © 2008 Silverman et al.; licensee BioMed Central Ltd. Proteomic analysis of the secretome of Leishmania donovani 1Department of Medicine (Division of Infectious Diseases), University of British Columbia, Faculty of Medicine, 2733 Heather St, Vancouver, British Columbia, V5Z 3J5, Canada 2Vancouver Coastal Health Research Institute, 2647 Willow St. Vancouver, British Columbia, V5Z 3P1, Canada 3Department Microbiology and Immunology, University of British Columbia, Faculty of Science, 2350 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada 4Canada's Michael Smith Genome Sciences Centre, 570 West 7th Ave - Suite 100, Vancouver, British Columbia, V5Z 4S6, Canada 5Bioinformatics Graduate Program, University of British Columbia, 100-570 West 7th Avenue, Vancouver, British Columbia, V5Z 4S6 Canada 6Laboratory of Parasitic Diseases, Division of Intramural Research, NIAID, National Institutes of Health, 4 Center Drive, Bethesda, Maryland, 20892, USA 7Department of Biochemistry and Molecular Biology, University of British Columbia, Faculty of Science, 2350 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada Corresponding author.J Maxwell Silverman: maxer/at/interchnage.ubc.ca; Simon K Chan: sichan/at/bcgsc.ca; Dale P Robinson: dale.p.robinson/at/gmail.com; Dennis M Dwyer: DDwyer/at/mail.nih.gov; Devki Nandan: dnandan/at/interchange.ubc.ca; Leonard J Foster: ljfoster/at/interchange.ubc.ca; Neil E Reiner: ethan/at/interchange.ubc.ca Received November 10, 2007; Revised January 22, 2008; Accepted February 18, 2008. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Leishmania and other intracellular pathogens have evolved strategies that support invasion and persistence within host target cells. In some cases the underlying mechanisms involve the export of virulence factors into the host cell cytosol. Previous work from our laboratory identified one such candidate leishmania effector, namely elongation factor-1α, to be present in conditioned medium of infectious leishmania as well as within macrophage cytosol after infection. To investigate secretion of potential effectors more broadly, we used quantitative mass spectrometry to analyze the protein content of conditioned medium collected from cultures of stationary-phase promastigotes of Leishmania donovani, an agent of visceral leishmaniasis. Results Analysis of leishmania conditioned medium resulted in the identification of 151 proteins apparently secreted by L. donovani. Ratios reflecting the relative amounts of each leishmania protein secreted, as compared to that remaining cell associated, revealed a hierarchy of protein secretion, with some proteins secreted to a greater extent than others. Comparison with an in silico approach defining proteins potentially exported along the classic eukaryotic secretion pathway suggested that few leishmania proteins are targeted for export using a classic eukaryotic amino-terminal secretion signal peptide. Unexpectedly, a large majority of known eukaryotic exosomal proteins was detected in leishmania conditioned medium, suggesting a vesicle-based secretion system. Conclusion This analysis shows that protein secretion by L. donovani is a heterogeneous process that is unlikely to be determined by a classical amino-terminal secretion signal. As an alternative, L. donovani appears to use multiple nonclassical secretion pathways, including the release of exosome-like microvesicles. Background Leishmania spp. are the causative agents of a group of tropical and subtropical infectious diseases termed the leishmaniases. These infections disproportionately affect poorer peoples in developing areas of the world. Because of the debilitating and disfiguring results of infection, these diseases are a great barrier to socioeconomic progress in endemic areas. As of 2001, it was estimated that 12 million people worldwide have been infected with leishmania, and 2 million new cases are believed to occur each year [1]. Recent environmental changes such as urbanization, deforestation, and new irrigation schemes have expanded endemic regions and have led to sharp increases in the number of reported cases [2-4]. In addition, visceral leishmaniasis is establishing itself in previously unaffected areas by piggy-backing on the spread of the HIV epidemic [5]. Leishmania co-infection with HIV has become a serious global health threat. The two infections are involved in a deadly synergy, because leishmania infection exacerbates the immunocompromised state of infected individuals, thereby promoting HIV replication and resulting in earlier onset of AIDS [6]. The combination of HIV co-infection, expansion of endemic regions, and evolving drug resistance [7] has created great need for more effective anti-leishmanial drugs and other control measures. Progress in controlling the leishmaniases requires improved appreciation of the biology of the parasite to allow novel treatment strategies to be designed. Members of the genus Leishmania are digenetic protozoans. The organisms exist either as flagellated, motile promastigotes within the alimentary canal of their phlebotomine sandfly vector or as nonmotile amastigotes that reside within phagolysosomes of mammalian mononuclear phagocytes. Promastigote surface coat constituents have been the focus of considerable interest [8-10], and many of these - including glycoproteins, proteoglycans, and glycolipids - have been shown to play protective roles [8,11,12]. Surface-associated molecules are considered to make up the vast majority of leishmania secreted material [9]. Through these studies, it has become evident that there are a number of unusual features that typify exocytosis by this group of trypanosomatids. For example, in these highly polarized cells, regulated secretion is thought to occur solely at the flagellar pocket, a deep invagination of the plasma membrane from which the single flagellum of leishmania emerges [9,13]. Leishmania are known to synthesize and traffic most surface molecules, such as lipophosphoglycan and leishmanolysin GP63, along the classical endoplasmic reticulum-Golgi apparatus-plasma membrane pathway [9]. As mentioned, these surface molecules are ultimately delivered to the flagellar pocket, and it is thought that the pocket retains its role as the primary if not sole site of secretion in nonflagellated amastigotes [9]. Thus far, no leishmania candidate virulence factors have been shown to traffic through the flagellar pocket. This is not surprising, however, given that no ultrastructural work has accompanied descriptions of leishmania candidate virulence factors, and little attention has been paid to their intracellular or extracellular trafficking pathways. Whether leishmania use a classical amino-terminal signal sequence peptide to direct the export of most secreted proteins through the flagellar pocket or a different mechanism is unclear. Two leishmania surface glycoproteins, a proteophosphoglycan and GP63, are initially synthesized with a cleavable amino-terminal signal sequence [9]. However, the vast majority of characterized leishmania secreted proteins have no identifiable secretion signal sequence, with the exception of those that are initially membrane bound [9,14,15]. The lack of a clear amino-terminal secretion signal sequence among the majority of characterized leishmania secreted proteins suggests the existence of important nonclassical pathways of secretion. Despite the potential importance of protein secretion by leishmania, only a small number of leishmania proteins have been examined in detail from this perspective [14,16-18]. Ideally, one would like to know the identities of all of the components of any complex system in order to fully comprehend functionality. Consequently, we set out to identify all, or as many as possible, of the proteins secreted by leishmania. To this end, we designed a quantitative proteomic approach based on SILAC (stable isotopic labeling of amino acids in culture) [19-21]. SILAC involves culturing cells with either normal isotopic abundance amino acids or with stable isotope-enriched amino acids (for instance, L-arginine versus 13C6-L-arginine) until essentially all proteins of the cell are labeled. The two populations or samples to be compared are then mixed and analyzed by nanoflow liquid chromatography-tandem mass spectrometry (LC-MS/MS). We used this approach to analyze the extent to which any given leishmania protein was secreted into promastigote conditioned medium (Cm) by relating it to the level of the same protein that remained cell associated (CA). In this report, we identified 358 proteins in combined Cm/CA mixtures from Leishmania donovani and, based on a quantitative analysis, we conclude that 151 were actively secreted. The general properties of the identified secreted proteins allowed us to postulate potential mechanisms of secretion as well as functional roles within the context of infection. Results Leishmania conditioned medium contains a multiplicity of enriched proteins The main objective of this study was to characterize as comprehensively as possible the proteins actively secreted by promastigotes of L. donovani into culture medium. Before proceeding with the SILAC and LC-MS/MS analysis, we sought to develop a system in which we were confident that the proteins we were detecting in Cm were not artifacts and were in fact present due to bona fide secretion. Previous investigations of protein secretion by leishmania were hampered by the presence of degradation products and by the requirement of the cells for serum [14,22]. In light of these complexities, we included a nontoxic protease inhibitor, soy bean trypsin inhibitor, in the promastigote culture medium during collection and isolation of Cm to minimize degradation of secreted proteins by proteases. Secondly, we reduced Cm collection time to 6 hours or less in order to allow culture of promastigotes under serum-free conditions. Pulse-chase labeling of leishmania with 35S-methionine followed by isolation of serum-free Cm showed clearly that leishmania secreted numerous proteins (Figure (Figure1a).1a
To control further for the possibility of false positive protein detection in Cm caused by inadvertent lysis of promastigotes either spontaneously (due to programmed cell death) or during isolation of Cm, using an enzymatic assay we measured the amount of cytosolic marker glucose 6-phosphate dehydrogenase (G6PD) [23] present in Cm. The total amount of G6PD activity detected in Cm was compared with activities found to be associated with serial dilutions of the total mass of promastigotes that was used to generate the Cm. As shown in Figure Figure1b,1b Quantitative mass spectrometry identifies a wide array of leishmania-secreted proteins Serum-free leishmania Cm collected from stationary phase promastigotes was fractionated either by one-dimension SDS-PAGE or by in-solution isoelectric focusing and analyzed by LC-MS/MS using a linear trapping quadrupole-Fourier transform hybrid mass spectrometer (see Materials and methods, below). We set three criteria that had to be met for any protein detected by mass spectrometry to be included in the leishmania 'secretome'. First, we only considered proteins to be identified if at least two unique tryptic peptide sequences from that protein were detected (see Materials and methods for peptide criteria limits). Second, we required a particular protein to be observed in at least three out of four independent experiments. This resulted in the identification of 358 proteins (listed in Additional data file 1) in the pooled Cm and CA samples, with an estimated false discovery rate of less than one protein in 200. Interestingly, by these criteria we did not detect G6PD in any of the LC-MS/MS analyses, probably because the amount of G6PD was below the detection limit of the mass spectrometer. The method of preparation of Cm for LC-MS/MS analysis did not provide sufficient amounts of protein to allow reliable use of standard methods for measuring total protein concentration (see Materials and methods, below), so we estimated the protein content of Cm samples from an initial LC-MS/MS analysis and mixed these with an equal amount of oppositely labeled CA protein. Because this method of equalization is imprecise, we normalized all Cm/CA ratios within an experiment to histone H2B (GeneDB:LmjF19.0050). H2B was consistently detected in Cm, most likely as a result of both general cell lysis and apoptosis [24,25]. After normalization, the values were loge transformed (Additional data file 2) and Cm/CA ratios for all identified proteins were calculated as the mean Cm/CA ratio for all peptides from that protein across all experiments (Additional data file 2) [26,27]. These SILAC ratios reflected the degree of enrichment of individual protein species in leishmania Cm, and a frequency distribution is shown in Figure Figure2.2
We used the Cm/CA ratio of histone H2B to define the third criterion for inclusion in the secretome. We considered leishmania proteins with a mean Cm/CA peptide ratio at least two standard deviations (1.7) above the ratio for histone H2B (after transformation = 0) to be actively secreted by leishmania (Figure (Figure2,2 We used Western blotting to examine a select group of proteins in paired Cm and CA samples to determine the extent to which this orthogonal method of detection would correlate with the SILAC/mass spectrometry analysis. Here we examined four proteins: heat shock protein (HSP)70, with a Cm/CA value of 1.86, above the cut-off of histone H2B plus two standard deviations (or +1.70); HSP83/HSP90, with a Cm/CA ratio of 1.50 falling just below the cut-off; elongation factor-1α (EF-1α) with a ratio of 0.69; and secreted acid phosphatase (SacP), which was not detected by LC-MS/MS. As shown in Figure Figure3,3
The results for SAcP both by mass spectrometry and Western blotting were of particular interest and appeared to be a special case. Whereas this ecto-enzyme, which was previously reported to have an amino-terminal secretion signal [28], was highly enriched in Cm (Figure (Figure3),3 The results of the Western blotting also indicated that there was minimal contamination of Cm by incidental lysis. Figure Figure33 Gene Ontology analysis of the leishmania secretome To develop an understanding of how protein secretion by leishmania might be related to specialized functions or processes, we used the Leishmania Genome [29] and the Gene Ontology (GO) [30] databases in conjunction with the Blast2GO analysis tool [31] to determine whether any classes of proteins were more likely to be found in among the leishmania secreted proteins. This analysis resulted in 85% of the proteins detected in leishmania Cm having one or more GO term assignments (Additional data file 3). After tallying the number of leishmania secreted proteins assigned to each GO term, it was clear that many of the secreted proteins (Figure (Figure4a)4a
Consistent with the biological process GO analysis, a full 50% of leishmania secreted proteins were involved in protein binding interactions, for example binding to ATP (GO:0005524), ions (GO:0043167), or other proteins (GO:0005515; Figure Figure4b).4b Of interest, there appeared to be a trend toward concentration of a distinct set of processes and functions in the group of 151 leishmania proteins making up the leishmania secretome. As shown in Figure Figure5a,5a
In addition to members of the secretome having pleiotropic functions, they were also predicted to have a variety of subcellular localizations. Nearly one-third of leishmania secreted proteins were predicted to be cytoplasmic (GO:0005737) by GO, and these had associations with both membrane bound (GO:0043227) and nonbound intracellular organelles (GO:0043228), including ribosomal proteins, nuclear proteins, mitochondrial proteins, and glycosomal proteins (Additional data file 3). Only five secreted proteins were predicted to be integral membrane proteins, and none of the secretome proteins were predicted to be associated with the endoplasmic reticulum. Bioinformatics analysis of secreted proteins in the leishmania genome We screened the leishmania genome database for proteins containing a classical amino-terminal secretion signal peptide, in order to generate a putative list of classically secreted proteins for comparison with the proteins identified by LC-MS/MS. We modified a bioinformatics approach previously used to identify proteins secreted by Mycobacterium tuberculosis [33] and applied it to the genome of Leishmania major [34]. Proteins were considered highly likely to be secreted if the sequence included a classical amino-terminal secretion signal peptide and lacked additional transmembrane (TM) domains. Additional TM domains would have suggested that the protein was membrane bound and therefore unlikely to be released from the cell. The majority of leishmania surface expressed proteins are associated with the plasma membrane via a glycophosphotidylinositol (GPI) lipid attachment [9], and some of these GPI-attached surface proteins, such as GP63, are known to disassociate from the membrane and can be detected in Cm [35]. In light of this, as a final step we screened the proteins positive for a signal sequence and negative for multiple TM domains for GPI-linkage attachment sites and considered positive proteins to be secreted (Additional data file 4). Using these parameters, we found that the leishmania genome encodes 217 proteins that contain a classical secretion signal peptide, of which 141 are annotated as hypothetical proteins (Additional data file 4). Of the remaining 76 proteins, approximately one-third appear to be gene duplications, leaving 50 unique leishmania proteins with a known or putative classical eukaryotic secretion signal peptide. It is of interest that only one of the proteins we predicted to be secreted via an amino-terminal secretion signal - LmjF16.0790, a chitinase - has previously been demonstrated to be secreted by leishmania promastigotes [16,36], although we did not detect this protein in our LC-MS/MS analysis. Our analysis also suggests that SAcP does not contain a classical secretion signal, contrary to a previous report [37]. Based upon the Von Heijne algorithm [34], the latter study predicted the presence of a 23-amino-acid amino-terminal 'signal peptide'. Subsequently, this leader peptide was shown to be sufficient for secretion of a green fluorescent protein fusion construct expressed in L. donovani [27]. The SignalP algorithm we used is the updated version of the 1985 Von Heijne algorithm. The lack of concordance in these predictions highlights the limitations of bioinformatics, while reinforcing the well known fact that signal sequences are highly variable. Our bioinformatics analysis also confirmed the annotation in the Leishmania Genome database [29] that none of the histidine secretory acid phosphatases found in the genomes of L. major or L. donovani infantum have classical amino-terminal secretion signals. Interestingly, only the membrane bound acid phosphatases of L. major are annotated as containing classical secretion signal peptides, whereas the same is not true of the orthologs in L. donovani infantum, and these membrane bound proteins would have been excluded by our TM domain screen. Only 14 of the proteins predicted to be secreted through a classical signal sequence-dependent mechanism were detected in leishmania Cm by MS, and only two of these, GeneDB:LmjF04.0310 and LmjF36.3880, had sufficiently high SILAC ratios to be included in the secretome (Additional data file 4). Although there are several possible explanations for failing to detect a protein by LC-MS/MS, the lack of correlation between the measured and the in silico predicted secretomes suggests that leishmania utilize nonclassical secretion signals and pathways to regulate the export of the majority of secreted proteins. Evidence that proteins released by leishmania may originate in exosome-like vesicles, apoptotic vesicles, and glycosomes Somewhat unexpected was the finding that leishmania Cm contained all of the proteins identified previously to be associated with exosomes isolated from both B lymphocytes and dendritic cells, with the exception of those for which the leishmania genome does not contain an ortholog (Additional data file 5). In fact, more than 10% of the proteins found in the leishmania secretome were previously detected in exosome-like microvesicles released from other eukaryotic cells (Table 1), including B lymphocytes [38], dendritic cells [24], and adipocytes [39]. Recently, mammalian adipocytes were shown to secrete microvesicles, which were referred to as adiposomes [39]. These adiposomes contained 98 proteins, 13 of which we concluded to be actively secreted (Table 1). At least 25 additional adiposome proteins were detected in leishmania Cm with relative abundances lower than the secretome cut-off (Additional data file 5). The concordance of the proteomic data between these higher eukaryotic secreted microvesicles and the leishmania secretome is remarkable. These findings suggested that leishmania secrete exosome/adiposome-like microvesicles carrying proteomic cargo that is similar in composition to host microvesicles. In support of this, using scanning electron microscopy, we observed 50 nm microvesicles specifically located at the mouth of the leishmania promastigote flagellar pocket (Figure 6a,b
Surprisingly, DNA-binding histone proteins were reliably detected by LC-MS/MS in Cm of stationary phase promastigotes (Additional data files 1 and 5). Histone proteins have been detected in dendritic cell exosomal preparations and were shown to enrich in these preparations after the cells were treated with an apoptosis-inducing agent [24]. The dendritic cell vesicles containing histone proteins were more electron dense and migrated to a slightly higher sucrose density than the exosomes [24]. This led the authors to conclude that the histone-containing vesicles were indeed a distinct population of vesicles, termed apoptotic vesicles or blebs [24]. The detection of histones in Cm of stationary phase leishmania (Additional data files 1 and 5), along with the significant number of apoptotic leishmania known to be present in a stationary phase population (approximately 43 ± 5%) [25], suggests that promastigotes may have been releasing apoptotic vesicles as well as exosomes. In addition to exosomal and apoptotic vesicle-associated proteins, we also found that the leishmania secretome included many of the major glycolytic enzymes that normally reside in glycosomes of kinetoplastid organisms [40] (Table 1 and Additional data file 5). Relevant to these findings, leishmania have been shown to utilize peroxisomal targeting signals (PTSs; PTS1 and PTS2) to direct proteins to the glycosome [41], and a screen of the leishmania genome identified approximately 100 proteins with either a PTS1 or a PTS2 targeting signal [42]. Remarkably, our MS analysis of leishmania Cm detected nearly half of these predicted glycosomal proteins, with ten being detected at high enough relative abundance to be considered bona fide secreted proteins (Table 1). These findings suggest that leishmania release either whole glycosomes or glycososomal cargo into the extracellular environment. Discussion To our knowledge, this report is the first proteomic analysis of protein secretion by Leishmania, or, for that matter, any other kinetoplast. This quantitative proteomic analysis showed that L. donovani released a wide array of proteins when in the stationary phase of growth (Additional data file 1). Based on previous studies concerned with the pathogenesis of leishmania as well as other intracellular pathogens [17,43], we anticipated that leishmania may secrete virulence effectors into their extracellular environment, including the cytosolic compartment of infected host cells. By examining the composition of the leishmania secretome and generating quantitative information concerning the relative enrichment of secreted proteins, we expected to identify candidate leishmania effector proteins that may be involved in virulence. As expected, protein export was found to be heterogeneous, with some proteins exported to a higher degree than they were retained by the cell, whereas for others the opposite was true (Figure (Figure2).2 Next, we inspected the leishmania secretome for potential virulence factors. Candidate virulence factors were divided into four categories: proteins putatively involved in intracellular survival; proteins with known immunosuppressive functions; proteins involved in signal transduction; and proteins involved with transport processes (Table 2). By far the largest class of candidate virulence factors was comprised of proteins that may be required for intracellular survival. The leishmania secretome showed a remarkable abundance of proteasome subunits (such as GeneDB:LmjF35.4850, LmjF36.1600, LmjF21.1700, LmjF21.1830, LmjF27.0190, LmjF36.1650, and LmjF34.0650) and proteases such as the oligopeptidases (GeneDB:LmjF09.0770; Tables 2 and 3, and Additional data file 1), of which many had high Cm/CA values. In addition, proteolysis was one of the most common GO terms assigned to the leishmania secreted proteins. Although the frequency of this term did not reach statistical significance (see Gene Ontology analysis of the leishmania secretome, under Results, above), this term appeared to be somewhat over-represented among the proteins in the upper half of the ratio distribution (Figures (Figures4a4a
Also likely to be involved in intracellular survival are secreted antioxidants, and more generally proteins with oxidoreductase activity, such as iron superoxide dismutase (GeneDB:LmjF32.1820). Other examples of these were found in the leishmania secretome (Figure (Figure5b5b An important inclusion to the category of proteins with functional roles in intracellular survival were nucleases, such as GeneDB:LmjF23.0200, an endoribonuclease, which was found to be the second most highly secreted protein (Table 3). This endoribonuclease belongs to a class of proteins that act on single-stranded mRNA and are thought to be inhibitors of protein synthesis [48]. These nucleases may aid in purine salvage, which is obligatory for leishmania because they are incapable of de novo purine synthesis [49]. Myo-inositol-1-phosphate synthase (GeneDB:LmjF14.1360), the protein with the highest relative abundance ratio (Table 3) and therefore the most enriched in the Cm, may also play a role in intracellular survival (Table 2). Leishmania myo-inositol-1-phosphate synthase has been shown to be essential for growth and survival in myo-inositol limited environments [50]. Leishmania myo-inositol-1-phosphate synthase knockouts were found to be completely avirulent [50] in mice, suggesting that the phagolysosomal lumen may be a myo-inositol limited environment. Myo-inositol-1-phosphate synthase is required for de novo biosynthesis of myo-inositol, a precursor of vital inositol phospholipids such as those found in the GPI membrane anchors of nearly all leishmania surface proteins and other glycoconjugates such as GP63 and lipophosphoglycan. The massive export of this essential enzyme into Cm is intriguing and warrants further study. The leishmania secreted protein kinetoplastid membrane protein-11 (GeneDB:LmjF35.2210), identified in the SILAC/mass spectrometry analysis, was previously characterized as having immunomodulatory effects on host cells during leishmania infection [51]. Furthermore, we found that the leishmania secretome contains an ortholog of the mammalian macrophage migration inhibitory factor (GeneDB:LmjF33.1750), a protein with known immunosuppressive and immunomodulatory properties [52] in humans. It is possible that this leishmania ortholog could share these functions and affect host immune responses during leishmania infection. Manipulation of host cell function via interference with signaling pathways is a well known virulence tactic of intracellular pathogens [53-57]. After internalization, leishmania infected macrophages exhibit defective signaling in response to various stimuli [54,55,57]. Based on our analysis, we estimate that at least ten secreted leishmania proteins are predicted to be involved in some manner in signal transduction (Table 2 and Additional data file 3). In this regard, we found that kinase activity was concentrated in the upper half of the secretome ratio distribution (Figure (Figure5b).5b Somewhat unexpected was the finding of proteins in leishmania Cm known to be involved in vesicular transport (Tables 2 and 1), such as the phosphoinositide binding protein discussed above, the small GTP-binding protein Rab1 (GeneDB:LmjF27.0760) and a putative ADP-ribosylation factor (GeneDB:LmjF31.2790). We have classified these proteins as candidate virulence factors because, although these transport vesicle regulatory proteins may normally regulate vesicle trafficking in leishmania, ectopically following secretion, they may have the potential to affect vesicle trafficking in infected cells. For example, it is tempting to speculate that these leishmania secreted proteins could directly affect phagosome maturation through modulating transport to and fusion with host multivesicular bodies, endosomes, and lysosomes. Another interesting and unexpected aspect of the leishmania secretome was the presence of numerous proteins related to translational machinery (Figure (Figure4a4a The protein secretion pathways utilized by leishmania are not well understood. According to our analysis, only two of the 151 proteins in the leishmania secretome contain a classical amino-terminal secretion signal (Additional data files 2 and 4). The fact that more than 98% of the secretome lacks a targeting signal indicates that nonclassical secretion pathways are probably the dominant means by which leishmania proteins are secreted. In support of this argument, the leishmania secretome included a large number of proteins previously identified as components of exosomes secreted from various higher eukaryotic cell types (Table 1). Leishmania Cm also contained many proteins shown to be cargo of clathrin-coated vesicles. Rat liver clathrin-coated vesicles were found to contain a total of 346 proteins, and in addition to the 30 translation-related proteins mentioned above, an further 30 of these proteins were detected in leishmania Cm, including clathrin (GeneDB:LmjF36.1630) and HSP70. Significantly, both clathrin and HSP70 have been found in exosomes released from various human cells [24,38,39]. In fact, the proteomes of these clathrin-coated vesicles and that of mammalian exosomes were strikingly similar [24,59-62]. Furthermore, leishmania have been shown to form clathrin-coated vesicles [63], and clathrin-directed trafficking in leishmania was shown to be essential for survival in macrophages [64]. Taken together, these findings suggest that leishmania may use clathrin-coated vesicles as a transport mechanism to direct vesicle trafficking at least, if not exocytosis of proteins from endosomal compartments to the extracellular milieu. Based on these findings, we propose that leishmania protein secretion probably involves the release of exosome-like vesicles, which may or may not be clathrin-coated. Moreover, we suggest that at least three distinct vesicular secretion processes contribute to the secretome, including exosomes, apoptotic vesicles, and glycosomes (Table 1). Exosomes are small vesicles, 50 to 100 nm in diameter, which are released by fusion of either multivesicular endosomes or secretory lysosomes with the plasma membrane of eukaryotic cells [65-67]. Exosomes were initially described in reticulocytes as a mechanism for shedding organellar proteins and excess transferrin receptor during differentiation into mature nuclei free red blood cells [68]. Somewhat later, the proteomes of B lymphocyte and dendritic cell exosomes were described [24,38]. Dendritic cell exosomes have attracted a significant amount of attention because of their immunostimulatory properties as cell-free, peptide-based vaccines [69-72]. The striking correspondence between the leishmania secretome and these exosomes strongly suggests that protein secretion by leishmania involves the release of intraluminal vesicles originating from either the tubular lysosome [73] or multivesicular endosomes, or both. It is tempting to speculate that leishmania exosomes, like dendritic cell exosomes [69,70], may be capable of modulating the host immune response, although it likely that their properties may be quite distinct. The formation of membrane blebs at the plasma membrane of apoptotic mammalian cells and their subsequent release are phenomena that have attracted significant attention [24,66,74]. As mentioned above, these apoptotic vesicles have been found to contain histone proteins and cytochrome c oxidase subunits. That leishmania undergo apoptosis is well established [25], and our finding that they release cytochrome c oxidase subunits and histones into Cm (Additional data files 1 and 5) suggests that they release apoptotic vesicles. Moreover, it has been shown that cultures of stationary phase leishmania promastigotes contain up to 43% apoptotic cells, and when the latter are removed by sorting the remaining nonapoptotic population is incapable of establishing and maintaining an infection [25]. These findings, taken together with our detection of apoptotic vesicle marker proteins, histones 1 through 4, in leishmania Cm (Additional data files 1 and 5), strongly suggest the possibility that leishmania apoptotic vesicles may be involved in pathogenesis. This could take the form of immune evasion, wherein (similar to activation of the 'silent phagocytosis' pathway used to internalize and clear very early apoptotic cells by mammalian macrophages [75]) these apoptotic vesicles would promote inhibition of macrophage activation before invasion by viable leishmania promastigotes. Somewhat more difficult to explain from our findings is the suggestion for whole glycosome release, based upon both the characterized and the putative glycosomal proteins we detected in leishmania Cm (Table 1). Notably, many of the leishmania Cm proteins that were bioinformatically predicted to be glycosomal by the presence of PTS1 or PTS2 have been identified in purified glycosomes of the closely related kinetoplast Trypanosoma brucei brucei [76]. Our identification of the two most prevalent leishmania glycosomal membrane proteins in promastigote Cm (Additional data file 5) suggests that intact glycosomes were being exported from the cell. This is as opposed to a model in which these organelles were fusing with the flagellar pocket to release their cargo, in which case we would not have expected to have detected glycosomal membrane proteins per se. As we suggested above to potentially explain the secretion of translation machinery proteins, release of glycosomal proteins may be related to a stress response, but the targeted release of glycosomes with a more specialized function remains a possibility. As previously stated, it is our hypothesis that the proteins with higher relative abundance in leishmania Cm are more likely to play an active role in pathogenesis than those proteins secreted to a lesser extent. Following this logic, export of proteins with lower Cm abundance may be related to either routine waste disposal or apoptotic blebbing, and these may be less likely to contribute to pathogenesis. Although this is a reasonable working model, it is not absolute and does not mean that proteins secreted in lesser abundance may not be of interest. In fact, EF-1α, a candidate virulence factor that has been shown to inhibit macrophage activation [17], had a Cm/CA peptide ratio in the lowest 20% of the ratio distribution (Figure (Figure2,2 It should be mentioned that three leishmania proteins previously described to be secreted, namely SacP [14], chitinase [36], and silent information regulator (SIR)2 [18], were not identified in this LC-MS/MS analysis of leishmania Cm. One possible explanation for why these identifications were not made is that they have extremely low intracellular concentrations, with nearly all of the synthesized protein being secreted. Under these conditions other proteins present in the cell at a higher concentration could mask the CA peptide signals in the mass spectrometry. Importantly, the SILAC/mass spectrometry analysis was designed to compute ratios of simultaneously detected spectra from mixed Cm and CA samples. The absence of a CA signal in the mass spectrometry would have provided a denominator of zero, thereby not allowing for the computation of a meaningful Cm/CA ratio and exclusion from the analysis. Thus, no matter how abundant these peptides might be in Cm, without a comparable CA signal these proteins would not be included in the leishmania secretome, as defined by this study. It is possible that this explanation may also account for why chitinase and SIR2 were not identified in the secretome, especially considering that neither have characterized intracellular functions. Finally, we conducted these experiments using L. donovani donovani. Sequencing of the L. donovani genome is currently underway. As such we used the completed L. major genome to assign protein identities to the mass spectra gathered from leishmania Cm. Although the genomes for these two species are thought to be very similar, as their similar life cycles, biology, and expression profiles would indicate [77], it is possible that genomic difference between species prevented identification of some Cm proteins. Examination of the secretome led to several additional findings worth noting. First, the number of proteins known to be associated with small vesicles outstripped by far the number of proteins identified that had classical secretion signals. This finding suggests that the main secretory route for leishmania involves the release of small vesicles. Second, for the majority of candidate virulence factors that were identified, it seems most likely that they may function to influence the survival of leishmania within the phagolysosome, although this remains to be formally tested. As the collection time for Cm was limited because of the need to culture organisms in the absence of serum, proteins in the secretome that may be involved in pathogenesis are likely to act during early stages of infection. During this early stage, they may contribute to the observed delay of phagosome maturation [78]. It has been proposed that delayed phagosome maturation represents a window of opportunity during which internalized promastigotes can differentiate into the more acid-tolerant amastigotes [79,80]. Whether the amastigote secretome is similar to or distinct from that of stationary phase promastigotes is not known at this time. However, given the relatively low stage-specific differences in gene expression that have been described [81], we do not regard significant differences to be likely. Third, targeting of virulence factors into host cell cytosol has been shown to be an effective strategy used by intracellular pathogens to remodel the environment and to influence host cell function [17,82-85]. After invading their macrophage hosts, leishmania have been shown to block cell activation, to inhibit microbicidal activity [86-88], and to attenuate antigen-presenting cell function [57,89,90]. A broad picture of the proteins secreted by leishmania in cell free culture provides a basis for investigation of effector proteins that may be active in host cells either within the phagolysosome or within host cytosol. Conclusion This quantitative proteomic analysis identified a large and diverse pool of proteins in leishmania Cm and allowed us to define the leishmania secretome based on measurements of relative protein abundance in Cm that could only be explained by active secretion. The identities of proteins within the secretome revealed many candidates for further studies concerned with potential contributions to virulence and pathogenesis as well as to investigate mechanisms of secretion. Moreover, the data also indicate clearly that leishmania use predominantly nonclassical targeting mechanisms to direct protein export. This leads us to propose a model in which protein export occurs largely through the release of microvesicles, perhaps including exosome-like vesicles, apoptotic vesicles, and glycosomes. Materials and methods Cell culture L. donovani Sudan strain 2S promastigotes were cultured in medium M199 supplemented with 10% fetal bovine serum (FBS; Gibco Cell Culture, Div. of Invitrogen Life Technologies, Gaithersburg, MD, USA), 1% penicillin and streptomycin, 20 mmol/l HEPES (Stem Cell Technologies, Vancouver, British Columbia, Canada), 6 μg/ml hemin, 2 mmol/l L-glutamine, 10 μg/ml folic acid, and 100 μmol/l adenosine at 26°C in a EchoTherm Chilling Incubator (Torrey Pines Scientific, San Marcos, CA, USA). Every third day the organisms were split 1:10 into fresh medium in 25 or 75 cm3 cell culture flasks. For SILAC analysis, promastigotes were transferred to custom made M199 without L-arginine and L-lysine (Caisson Laboratories, North Logan, UT, USA) supplemented with 10% partially dialyzed FBS (Gibco), 1% penicillin and streptomycin, 20 mmol/l HEPES (Stem Cell Technologies), 6 μg/ml hemin, 2 mmol/l L-glutamine, 10 μg/ml folic acid, 100 μmol/l adenosine, and one of two SILAC media formulations (normal isotopic abundance arginine [42 mg/l] and lysine [73 mg/l]; and 13C6-arginine [43.5 mg/l] and 2H4-lysine [75 mg/l]) at 26°C. Organisms were cultured in this medium for at least 14 days and split 1:10 every third day, in order to achieve 100% labeling of cellular proteins before analysis. Stable isotope-labeled amino acids were purchased from Cambridge Isotope Laboratories (Andover, MA, USA). Except where otherwise noted, reagents were obtained from the Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Isolation of promastigote Cm Stationary phase promastigotes that had been grown either in medium containing normal isotopic abundance arginine and lysine or in medium containing 13C6-arginine 2H4-lysine L were collected by centrifugation at 300 × g for 10 minutes in a Beckman GS-6R centrifuge (Beckman-Coulter, Fullerton, CA, USA) and washed in Hanks balanced salt solution. Organisms were then concentrated tenfold by re-suspension in medium M199 without FBS and supplemented with 2 mmol/l L-glutamine, 10 mmol/l HEPES, 10 μg/ml soya bean trypsin inhibitor (Sigma-Aldrich), and either normal isotopic arginine and lysine or 13C6-Arg and 2H4-Lys in the concentrations given above for 4 to 6 hours at 26°C. Cm was isolated from cells by centrifugation at 300 × g for 10 minutes in a Beckman GS-6R. Supernatant was then subjected to centrifugation once more to ensure that no cells remained in suspension. Cm and cell pellets were either used immediately for enzymatic analysis or stored at -20°C for mass spectrometry analysis. A minimum of 5 × 108 promastigotes in culture was required to generate Cm with signals of adequate strength for mass spectrometry analysis. Four times as many stationary phase organisms were required to generate sufficient Cm for detection of proteins by either metabolic labeling and autoradiography or by Western blotting. Two billion organisms were cultured in M199 containing normal isotopic arginine and lysine (Sigma-Aldrich). For autoradiography, cells were collected and washed as above, and then starved of methionine by resuspension in RPMI-1640 medium without methionine and cysteine (Sigma-Aldrich) with 1% FBS. After 1 hour 50 μCi/ml of 35S methionine (Sigma-Aldrich) was added and cells were cultured for a further 2 hours to allow labeling to occur. After washing to remove serum, cells were incubated for 4 hours in serum-free RPMI-1640 medium without methionine and cysteine, containing 10 mmol/l L-glutamine, 1 mmol/l HEPES, and 10 μg/μl Soya bean trypsin inhibitor, at which point the cells were separated from the Cm by low speed centrifugation to avoid mechanical lyses of cells. Pelleted cells were lysed on ice in lysis buffer (50 mmol/l Tris [pH 7.4], 1% Triton X-100, 0.15 mol/l NaCl, 1 mmol/l EGTA, 1 mmol/l phenylmethylsulfonyl fluoride, 10 μg aprotinin/ml, and 10 μg leupeptin/ml). Cell lysates were clarified by centrifugation in a microcentrifuge at maximum speed for 20 min at 4°C. The resulting WCL supernatants and the Cm were precipitated with trichloroacetic acid at 10% final concentration. The precipitates were solubilized in Laemmli sample buffer and equal counts/minute of Cm and WCL were separated by SDS-PAGE (5% to 20% gradient) followed by autoradiography. For Western blotting, Cm was collected as above, but organisms were concentrated in normal isotopic M199. After separating Cm from the cells, WCLs were generated by sonicating the cell pellets to mimic lysis that may have occurred inadvertently during culture or centrifugation. Briefly, cell pellets were solubilized in 0.5 mmol/l Tris Laemmli sample buffer without SDS, bromophenol blue, or β-mercaptoethanol, but including protease inhibitors leupeptin and aprotinin both at 1 μg/ml and 10 μg/ml phenylmethylsulphonyl fluoride. The solution was sonicated three times at a power setting of 3 for 10 seconds. The lysate was cleared of insoluble material by centrifugation for 5 minutes at 10,000 × g. Following clarification the supernatant proteins were precipitated following the procedure bellow. The pellet was resuspended in Laemmli sample buffer without β-mercaptoethanol or bromophenol blue. Protein precipitation For Western blotting and metabolic labeling analysis, proteins present within promastigote Cm were precipitated using pyrogallol red, as described previously [91]. Briefly, sodium deoxycholate was added to Cm to a final concentration of 0.02% and the solution was mixed for 30 minutes at 4°C to facilitate precipitation. Cm was then mixed with an equal volume of pyrogallol red solution (containing 0.05 mmol/l pyrogallol red, 0.16 mmol/l sodium molybdate, 1.0 mmol/l sodium oxalate, 50 mmol/l succinic acid, and 20% methanol [vol/vol]) and the pH adjusted to 2.0 with 2N HCl. The resulting solution was incubated at room temperature for 1 to 2 hours followed by 12 to 24 hours at 4°C. The Cm protein precipitates were harvested by centrifugation at 11,000 × g for 60 minutes at 4°C followed by two washes with ice cold acetone. The pellets were allowed to air dry before solubilization in Laemmli sample buffer without β-mercaptoethanol or bromophenol blue at 95°C for 30 minutes. Protein concentrations of the Cm and WCLs were measured using the BioRad DC Protein Assay (BioRad Laboratories Inc., Hercules, CA, USA). G6PD assay Promastigote cell pellets were lysed by sonication to generate a WCL in 1 ml medium M199 with the appropriate concentrations of either normal isotope or nonradioactive isotope arginine and lysine, 1 mmol/l L-glutamine, 1 mmol/l HEPES, 10 μg/ml soya bean trypsin inhibitor, protease inhibitors leupeptin and aprotinin both at 1 μg/ml, and 10 μg/ml phenylmethylsulphonyl fluoride. After clearance by centrifugation at 11,000 × g, serial twofold dilutions of the lysate were made in medium M199 supplemented as above to yield final concentrations of 50%, 25%, 10%, 5%, and 1% (vol/vol). The concentrations of G6PD in 100 μl of Cm and in serial dilutions of WCL were assayed in 55 mmol/l Tris-HCl and 3.3 mmol/l MgCl2 buffer at pH 7.8, containing 3.3 mmol/l glucose-6-phosphate and 2 mmol/l NADP. Enzyme was obtained from the Sigma Chemical Company for a positive control. To generate a reference, 0.01 units of G6PD were stabilized in 5.0 mmol/l glycine with 0.01% bovine serum albumin (pH 8.0) and assayed along with sample and WCL dilutions. Enzyme reactions were carried out at 30°C and the change in absorbance, caused by changing NADP concentration, over 5 minutes was measured at 340 nm. LC-MS/MS of promastigote conditioned medium and data analysis To identify proteins specifically secreted by leishmania into culture medium, direct quantitative comparisons of protein abundance in Cm versus CA were made on a protein-by-protein basis. The Cm was collected from leishmania grown in medium containing heavy isotopes of arginine and lysine, and compared with cell-associated material prepared from promastigotes grown in medium containing normal isotopic abundance amino acids. In some cases the reciprocal analysis was also carried out as well with identical results. Approximately equal amounts of labeled and unlabeled protein (estimated from a preliminary LC-MS/MS analysis) from Cm and CA were mixed together and analyzed either by gel-enhanced LC-MS/MS exactly as described previously [92] or by peptide-level isoelectric focusing (IEF) combined with LC-MS/MS. For IEF, the protein mixture was solubilized in digestion buffer (50 mM NH4OH, 1% sodium deoxycholate, pH 8.0), denatured by heating to 99°C for 5 minutes, reduced by incubation with 1 μg dithiothreitol for 30 minutes at 37°C, alkylated with 5 μg iodoacetamide for 30 minutes at 37°C and finally digested by the addition of 1 μg porcine trypsin (Promega, Madison, WI, USA) overnight at 37°C. After digestion, the sample was acidified by addition of an equal volume of sample buffer (3% acetonitrile, 1% trifluoroacetic acid, and 0.5% acetic acid) and the deoxycholate that fell out of solution was pelleted at 16,100 × g for 5 minutes. Peptide mixtures were then desalted on STop-And-Go Extraction (STAGE) tips [93] before being resolved into 24 fractions from pH 3 to 10 on an OFFGEL IEF system (Agilent Technologies, Santa Clara, CA, USA), in accordance with the manufacturer's instructions. Fractions from the IEF were diluted with an equal volume of sample buffer, and each was desalted again on a STAGE tip. Each gel or OFFGEL fraction was analyzed on a linear trapping quadrupole-Fourier transform tandem mass spectrometer, as described previously [19]. Fragment spectra were extracted with ExtractMSN.exe (v3.2) using the default parameters (ThermoFisher Scientific, Ottawa, ON, CA); monoisotopic peak assignments were corrected with DTASuperCharge (default parameters [94]); and the resulting peak list was searched against the protein database for L. major plus the sequences of all human keratins and porcine trypsin (5 November 2006 version, 8,324 sequences) using Mascot (v2.1 [95]). MSQuant [94] was used to parse Mascot result files, to recalibrate mass measurements, and to extract quantitative ratios. The final nonredundant list of proteins was generated using finaList.pl, an in-house script available on our website [96]. The false discovery rate for protein identifications based on two or more peptides with a measured mass accuracy under 3 ppm (the overall average was 0.61 ppm), a Mascot score of 25 or greater, and length 8 residues or more was estimated to be less than 0.5%, using reversed database searching. All identified peptides with their associated parameters can be found in Additional data file 1. SILAC ratios were extracted exactly as described previously [19]. The mean loge transformed ratios from four independent analyses and the relative standard deviations can be found in Additional data file 2. Western blotting Following isolation of Cm, lysis of the corresponding cell pellet, and precipitation of proteins in both fractions, equivalent amounts of protein from the Cm and WCL were fractionated by SDS-PAGE. Proteins were transferred to nitrocellulose and probed with anti-EF-1α (Upstate Biotechnologies Inc., Lake Placid, NY, USA) following the manufacturer's instructions, as well as leishmania-specific antibodies to histidine secreted acid phosphatase [97] and against HSP70 and HSP90 [98] (a kind gift from Dr Joachim Clos). Scanning electron microscopy Stationary phase promastigotes were washed in phosphate-buffered saline and fixed in 2.5% gluteraldehyde in 0.1 mol/l sodium cacodylate buffer (pH 7.2) containing 0.146 mol/l sucrose and 5 mmol/l CaCl2 at 22°C under vacuum in a microwave: 2 minutes at 100 W, 2 minutes without microwaves, 2 minutes with 100 W, and then repeated. Subsequently, fixed organisms were rinsed in the same buffer in the microwave for 40 seconds at 100 W two times and post-fixed in 1% OsO4 in 0.1 mol/l sodium cacodylate containing 2 mmol/l CaCl2 and 0.8% potassium ferricyanide (Polysciences, Warrington, PA, USA) at 22°C under vacuum in a microwave following the same steps used in the gluteraldehyde fixation. Cells were washed in distilled water at room temperature and allowed to adhere to poly-L-lysine (Sigma) coated coverslips. Subsequently the coverslips were dehydrated through an ascending ethanol series from 50% to 100%, each for 40 seconds at 100 W in a microwave. The fixed cells were critically point dried with liquid CO2 in a Balzars 020 Critical Point Dryer (Balzars Union Ltd, Lichtenstein) and coated with gold palladium using a Nanotech SEMPrep II sputter coater (Nanotech Ltd., Prestwick, U.K.). Samples were observed and imaged using a Hitachi S-2600 VPSEM (Hitachi High Technologies, Finchampstead, Wokingham, Berkshire, UK) at the University of British Columbia Bioimaging Facility. Bioinformatics screen of the genome of Leishmania major to identify candidate secreted proteins The genome of L. major was accessed at the GeneDB L. major database [29]. Predictions of signal peptides and signal peptidase cleavage sites were made by SignalP [99]. Once these were provisionally identified, a filter was applied to remove those that contained more than one TM region predicted by TMpd [100]. Proteins with just one TM region were again screened to filter out those whose single TM domain did not overlap with the signal peptide coordinates. Finally, these putative classically secreted, non-TM proteins were screened for GPI attachment sites at the carboxyl-terminus using the GPI prediction program GPI-SOM [101]. Gene Ontology GO [30] annotations were performed using Blast2GO [31]. A nonredundant database was used as reference for Blastp searches with an expectation value minimum of 1 × e-3 and a high scoring segment pair cut-off of 33. Annotations were made with default parameters. Briefly, the pre-eValue-Hit-Filter was 1 × e-6, the Annotation cut-off was 55, and the GO Weight was 5. The statistical framework GOSSIP [32] was used to identify statistically enriched GO terms associated with leishmania secreted proteins when compared to the GO terms associated with all of the proteins identified in leshmania Cm. GOSSIP generates 2 × 2 contingency tables for each GO term in the test group and uses a Fisher's exact test to calculate P values for each term. The P values are then adjusted for multiple testing by calculation of the false discovery rate and the family wise error rate [32]. Statistical analysis Statistical analyses of Cm/CA ratios and G6PD concentrations were performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). Abbreviations CA, cell associated; Cm, conditioned medium; EF-1α, elongation factor-1α; FBS, fetal bovine serum; G6PD, glucose 6-phosphate dehydrogenase; GO, Gene Ontology; GPI, glycophosphotidylinositol; HSP, heat shock protein; IEF, isoelectric focusing; LC-MS/MS, liquid chromatography-tandem mass spectrometry; PTS, peroxisomal targeting signal; SacP, secreted acid phosphatase; SILAC, stable isotopic labeling of amino acids in culture; SIR, silent information regulator; TM, transmembrane; WCL, whole cell lysate. Authors' contributions JMS was involved in study design, data collection and analysis, interpretation of results and manuscript preparation. SKC helped in design and implementation of the bioinformatics screen. DPR was involved in LC-MS/MS data collection and analysis. DD provided leishmania-specific antibodies to secreted acid phosphatase. DN helped with design of biochemical analyses. LJF was involved in study design, data collection and analysis, and manuscript preparation. NER was involved in study design, interpretation of results, and manuscript preparation. Additional data files The following additional data files are available with the online version of this paper. Additional data file 1 is a table listing all the proteins, and the peptides contributing to their identification, detected in leishmania Cm. Additional data file 2 is a table showing a complete list of the SILAC ratios calculated for each Cm protein in each experiment, including the means of the four experiments. Additional data file 3 is a table listing all the GO terms associated with the leishmania Cm proteins. Additional data file 4 is a table listing the proteins predicted by bioinformatics to be secreted under the control of an amino-terminal secretion signal peptide; also shown here are the proteins with predicted GPI attachment sites and those proteins determined to be present in leishmania Cm by the SILAC LC-MS/MS analysis. Additional data file 5 is a table listing the leishmania Cm proteins, their mean SILAC ratios, and any documented microvesicle associations for these proteins. Additional data file 1 358 proteins had at least two nonoverlapping peptides that were detected and quantified in three or more individual analyses of leishmania Cm proteins. The peptides corresponding to each identification are shown. Protein identities were determined as described in Materials and methods and for Tables 1 to 3. Click here for file(189K, xls) Additional data file 2 After determining which proteins were to be considered for analysis (as described in Materials and methods and for Additional Data File 1), the measured Cm/CA ratios were normalized to the measured value of histone H2B in each independent experiment. The normalized values were then log normal (Ln) transformed (mean Ln transformed Cm/CA ratio, experiments [Exps] 1 to 4) to reduce the spread of the data. The means of the Ln transformed ratios for each protein identity were then calculated (mean Ln transformed values). The relative standard deviations of the peptide ratios for each analysis are included. Click here for file(109K, xls) Additional data file 3 GO annotation of the proteins detected in leishmania Cm. *Proteins with amino-terminal secretion signal peptides, and †proteins shown to be antigenic. GO IDs lists the GO identification number associated with each protein, and GO Term lists the term associated with each GO ID. C, cellular compartment; F, molecular function; P, biologic process. Click here for file(179K, xls) Additional data file 4 Leishmania proteins predicted to be classically secreted by a genome wide screen for proteins containing an amino-terminal secretion signal peptide. MS, proteins detected in the SILAC/mass spectrometry analysis; § proteins detected by mass spectrometry with ratios above the secretome cut-off; GPI, proteins found to contain a GPI attachment site; *, proteins previously reported to be secreted by leishmania. Click here for file(34K, xls) Additional data file 5 Proteins with mean Cm/CA peptide ratios greater that two standard deviations above that of histone H2B were considered enriched. *Proteins with amino-terminal secretion signal peptides, and †proteins shown to be antigenic. Microvesicle Association displays the vesicles associated with the protein ID. AP, adipocyte adiposome; BC, B-cell lymphocyte exosome; DC, dendritic cell exosome; Gly, glycosome. Click here for file(57K, xls) Acknowledgements The authors would like to thank Dr Joachim Clos for the kind gift of leishmania-specific antibodies, and the University of British Columbia Bioimaging facility for their excellent technical assistance with electron microscopy. This work was supported by Canadian Institutes of Health grants MOP-8633 and MOP-83063 (NER), and MOP-77688 (LJF). LJF is the Canada Research Chair in Organelle Proteomics, a Michael Smith Foundation Scholar, and a Peter Wall Institute Early Career Scholar. Additional support was provided by an award from the CIHR/MSFHR Strategic Training Program in Bioinformatics (SKC) and by an infrastructure grant from the Michael Smith Foundation (RUA042021). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
Nat Rev Microbiol. 2007 Nov; 5(11):873-82.
[Nat Rev Microbiol. 2007]Public Health Rev. 2001; 29(1):37-47.
[Public Health Rev. 2001]East Mediterr Health J. 2003 Jul; 9(4):518-33.
[East Mediterr Health J. 2003]Indian J Med Res. 2005 Apr; 121(4):407-14.
[Indian J Med Res. 2005]Med Microbiol Immunol. 2001 Nov; 190(1-2):65-7.
[Med Microbiol Immunol. 2001]Proc Natl Acad Sci U S A. 2003 Aug 5; 100(16):9536-41.
[Proc Natl Acad Sci U S A. 2003]Gene. 2002 Aug 21; 296(1-2):139-50.
[Gene. 2002]EMBO J. 2002 Sep 2; 21(17):4458-69.
[EMBO J. 2002]J Biol Chem. 1997 Feb 7; 272(6):3799-805.
[J Biol Chem. 1997]Microbiol Mol Biol Rev. 2002 Mar; 66(1):122-54; table of contents.
[Microbiol Mol Biol Rev. 2002]Microbiol Mol Biol Rev. 2002 Mar; 66(1):122-54; table of contents.
[Microbiol Mol Biol Rev. 2002]Mol Biochem Parasitol. 1987 Dec; 26(3):289-96.
[Mol Biochem Parasitol. 1987]Nature. 2004 Jul 22; 430(6998):463-7.
[Nature. 2004]Mol Biochem Parasitol. 1987 Dec; 26(3):289-96.
[Mol Biochem Parasitol. 1987]Gene. 1998 Feb 27; 208(2):315-22.
[Gene. 1998]Kinetoplastid Biol Dis. 2005 Jan 24; 4(1):1.
[Kinetoplastid Biol Dis. 2005]J Proteome Res. 2006 Jan; 5(1):64-75.
[J Proteome Res. 2006]Mol Cell Proteomics. 2002 May; 1(5):376-86.
[Mol Cell Proteomics. 2002]Mol Biochem Parasitol. 1987 Dec; 26(3):289-96.
[Mol Biochem Parasitol. 1987]Exp Parasitol. 1988 Dec; 67(2):199-209.
[Exp Parasitol. 1988]J Biol Chem. 2003 Oct 17; 278(42):40757-63.
[J Biol Chem. 2003]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]Proc Natl Acad Sci U S A. 2006 Sep 12; 103(37):13837-42.
[Proc Natl Acad Sci U S A. 2006]Stem Cells. 2005 Oct; 23(9):1367-77.
[Stem Cells. 2005]Cell. 2006 Apr 7; 125(1):187-99.
[Cell. 2006]J Biol Chem. 2002 May 17; 277(20):17994-8001.
[J Biol Chem. 2002]Nat Genet. 2000 May; 25(1):25-9.
[Nat Genet. 2000]Bioinformatics. 2005 Sep 15; 21(18):3674-6.
[Bioinformatics. 2005]Genome Inform. 2005; 16(1):106-15.
[Genome Inform. 2005]Infect Immun. 2000 Apr; 68(4):2323-7.
[Infect Immun. 2000]Science. 2005 Jul 15; 309(5733):436-42.
[Science. 2005]Microbiol Mol Biol Rev. 2002 Mar; 66(1):122-54; table of contents.
[Microbiol Mol Biol Rev. 2002]Infect Immun. 2000 Jan; 68(1):80-6.
[Infect Immun. 2000]Gene. 1998 Feb 27; 208(2):315-22.
[Gene. 1998]Gene. 1997 Sep 1; 196(1-2):127-37.
[Gene. 1997]Science. 2005 Jul 15; 309(5733):436-42.
[Science. 2005]Cell. 2006 Apr 7; 125(1):187-99.
[Cell. 2006]J Exp Med. 1996 Mar 1; 183(3):1161-72.
[J Exp Med. 1996]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]Endocrinology. 2007 Aug; 148(8):3850-62.
[Endocrinology. 2007]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]Proc Natl Acad Sci U S A. 2006 Sep 12; 103(37):13837-42.
[Proc Natl Acad Sci U S A. 2006]Endocrinology. 2007 Aug; 148(8):3850-62.
[Endocrinology. 2007]Biochim Biophys Acta. 2006 Dec; 1763(12):1463-77.
[Biochim Biophys Acta. 2006]FEMS Microbiol Rev. 2004 Nov; 28(5):603-43.
[FEMS Microbiol Rev. 2004]J Biol Chem. 2002 Dec 20; 277(51):50190-7.
[J Biol Chem. 2002]Mol Biochem Parasitol. 2006 Jun; 147(2):193-206.
[Mol Biochem Parasitol. 2006]Infect Immun. 2000 Dec; 68(12):6997-7002.
[Infect Immun. 2000]J Immunol. 2005 Sep 1; 175(5):3214-24.
[J Immunol. 2005]J Biol Chem. 2005 Feb 11; 280(6):4037-47.
[J Biol Chem. 2005]J Immunol. 2002 Jul 15; 169(2):898-905.
[J Immunol. 2002]Cell Microbiol. 2007 Jan; 9(1):84-96.
[Cell Microbiol. 2007]J Bacteriol. 1999 Jun; 181(12):3810-5.
[J Bacteriol. 1999]Antimicrob Agents Chemother. 2005 Sep; 49(9):3682-9.
[Antimicrob Agents Chemother. 2005]Mol Biochem Parasitol. 2002 Mar; 120(1):151-6.
[Mol Biochem Parasitol. 2002]Scand J Immunol. 2005 Apr; 61(4):337-42.
[Scand J Immunol. 2005]Mol Endocrinol. 2007 Jun; 21(6):1267-80.
[Mol Endocrinol. 2007]J Leukoc Biol. 2000 Apr; 67(4):464-70.
[J Leukoc Biol. 2000]J Immunol. 1991 Apr 15; 146(8):2747-53.
[J Immunol. 1991]Infect Immun. 1999 Aug; 67(8):4055-63.
[Infect Immun. 1999]Infect Immun. 1995 Nov; 63(11):4495-500.
[Infect Immun. 1995]Mol Biol Cell. 2005 Jun; 16(6):2809-21.
[Mol Biol Cell. 2005]J Biol Chem. 2002 Dec 20; 277(51):50190-7.
[J Biol Chem. 2002]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]J Exp Med. 1996 Mar 1; 183(3):1161-72.
[J Exp Med. 1996]Endocrinology. 2007 Aug; 148(8):3850-62.
[Endocrinology. 2007]Mol Biol Cell. 2005 Jun; 16(6):2809-21.
[Mol Biol Cell. 2005]J Cell Sci. 2005 Aug 15; 118(Pt 16):3631-8.
[J Cell Sci. 2005]Exp Parasitol. 2005 Jan; 109(1):33-7.
[Exp Parasitol. 2005]Curr Opin Cell Biol. 2004 Aug; 16(4):415-21.
[Curr Opin Cell Biol. 2004]J Biochem. 2006 Jul; 140(1):13-21.
[J Biochem. 2006]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]J Exp Med. 1996 Mar 1; 183(3):1161-72.
[J Exp Med. 1996]J Immunol. 2001 Jun 15; 166(12):7309-18.
[J Immunol. 2001]J Biol Chem. 2003 Aug 8; 278(32):29400-9.
[J Biol Chem. 2003]Nat Med. 1998 May; 4(5):594-600.
[Nat Med. 1998]Proc Natl Acad Sci U S A. 2006 Sep 12; 103(37):13837-42.
[Proc Natl Acad Sci U S A. 2006]Mol Biol Cell. 2001 Aug; 12(8):2364-77.
[Mol Biol Cell. 2001]Int Immunol. 2005 Jul; 17(7):879-87.
[Int Immunol. 2005]J Biol Chem. 2002 Dec 20; 277(51):50190-7.
[J Biol Chem. 2002]Proc Natl Acad Sci U S A. 2006 Sep 12; 103(37):13837-42.
[Proc Natl Acad Sci U S A. 2006]Mol Biochem Parasitol. 1987 Dec; 26(3):289-96.
[Mol Biochem Parasitol. 1987]J Biol Chem. 2005 Feb 4; 280(5):3847-61.
[J Biol Chem. 2005]Kinetoplastid Biol Dis. 2005 Jan 24; 4(1):1.
[Kinetoplastid Biol Dis. 2005]J Immunol. 2003 Nov 1; 171(9):4672-9.
[J Immunol. 2003]Proteomics. 2006 Jun; 6(11):3275-93.
[Proteomics. 2006]Mol Microbiol. 2004 Nov; 54(4):1051-62.
[Mol Microbiol. 2004]Clin Immunol. 2005 Mar; 114(3):256-65.
[Clin Immunol. 2005]Infect Immun. 2006 May; 74(5):2613-8.
[Infect Immun. 2006]J Biol Chem. 2002 Dec 20; 277(51):50190-7.
[J Biol Chem. 2002]Parasitol Today. 1999 Aug; 15(8):325-32.
[Parasitol Today. 1999]Adv Immunol. 2000; 74():275-317.
[Adv Immunol. 2000]Appl Environ Microbiol. 2004 Jan; 70(1):610-2.
[Appl Environ Microbiol. 2004]J Proteome Res. 2006 Jan; 5(1):64-75.
[J Proteome Res. 2006]Mol Cell Proteomics. 2006 Dec; 5(12):2252-62.
[Mol Cell Proteomics. 2006]Anal Chem. 2003 Feb 1; 75(3):663-70.
[Anal Chem. 2003]Mol Cell Proteomics. 2006 Dec; 5(12):2252-62.
[Mol Cell Proteomics. 2006]J Proteome Res. 2006 Jan; 5(1):64-75.
[J Proteome Res. 2006]Exp Parasitol. 1987 Oct; 64(2):157-64.
[Exp Parasitol. 1987]Mol Biochem Parasitol. 1995 Mar; 70(1-2):107-18.
[Mol Biochem Parasitol. 1995]Nat Protoc. 2007; 2(4):953-71.
[Nat Protoc. 2007]Nat Genet. 2000 May; 25(1):25-9.
[Nat Genet. 2000]Bioinformatics. 2005 Sep 15; 21(18):3674-6.
[Bioinformatics. 2005]Genome Inform. 2005; 16(1):106-15.
[Genome Inform. 2005]